Loading
A phase 2 trial in lung cancer, run by The Netherlands Cancer Institute, not yet recruiting.
RADICAL-IO: thRee Cycles of immunotherApy Without raDical Therapy In mediCALly InOperable Stage I Non-small Cell Lung Cancer is a phase 2, interventional study registered as NCT07808138 by The Netherlands Cancer Institute, with a registry enrolment figure of 30 participants, started 2026-11 and due to reach its primary completion in 2029-12-01. Interventions recorded: Cemiplimab 350 mg IV. Conditions listed: Non Small Cell Lung Cancer; Immunotherapy. Primary outcome: Recurrence free survival (RFS) as per RECIST 1.1. Lung eligibility wording from the registry: "tumor diameter ≤ 3 cm) NSCLC according to the 9th AJCC/UICC staging classification (30)". Sites: Netherlands. No results are recorded here; the registry entry is the source.
Shares Regeneron, Resectable stage I to III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Regeneron, Resectable stage I to III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Resectable stage I to III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Resectable stage I to III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Resectable stage I to III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Resectable stage I to III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Resectable stage I to III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Resectable stage I to III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.